Eisai poaches senior Pfizer and Sanofi execs for neurology group
pharmafile | April 26, 2016 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim
Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions at Pfizer and Sanofi.
Paul Hawthorne (pictured) joins the team as senior vice president, US commercial where he will lead the sales and marketing teams across America.
He held senior positions at Sanofi spanning a career there which lasted 24 years. Most recently, Hawthorne held the role of vice president of sales with responsibility for leading the French firm’s retain, hospital and long-term care sales forces. Previously, he served as VP and head of Go To Market Center of Excellence as well as VP and head of Sanofi’s oncology business unit.
Ivan Cheung, chairman and CEO at Eisai, reacts: “With his proven record for driving organisational and brand growth, we are excited to have Paul on our team. We look forward to his contributions to our commercial organisation to maximise our neurology brands, and help in ensuring that the appropriate patients have access to our products.”
Also joining the Eisai neurology team is Beyhan Zaim who will take the role of VP, commercial development and Alzheimer’s disease global lead.
She joins from Pfizer, where she held a number of senior roles. Most recently she served as Pfizer’s VP of external opportunities and new business, and VP of commercial development for its primary business care unit.
Zaim will take the lead on the firm’s neurology commercial development team to create and drive commercial strategies for pipeline compounds and approaching the commercialisation stage.
Cheung adds: “With her deep expertise in the commercial development of in-line and pipeline compounds, and extensive knowledge of Alzheimer’s disease and other neurodegenerative disease states, Beyhan is a tremendous addition to Eisai.”
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
